NEW BRUNSWICK, N.J. / Aug 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2023 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Thursday, September 7th. Ashley McEvoy, EVP, Worldwide Chairman, MedTech along with executives from Abiomed will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).
This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com.
A webcast and podcast replay will be available approximately 48 hours after the live webcast.
| Last Trade: | US$155.92 |
| Daily Change: | 3.17 2.08 |
| Daily Volume: | 8,210,942 |
| Market Cap: | US$375.770B |
June 13, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
